PHIO · Phio Pharmaceuticals Corp.
$0.92
+0.03 (+2.88%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“The Company has limited cash resources, has incurred recurring operating losses and negative cash flows from its operations since its inception and has not yet recognized any product revenues. These factors have previously raised doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$10.36M
Shares
11.62M
Volume · Oct 21
67.02K
Avg daily vol (3M)
140.98K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.89
Open$0.86
Day$0.86–0.91
52W close$0.86–2.16
Avg vol 30d101K
Short int89K · 0.8% float · 1.0d
Short vol71%
Last earningsMar 18, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$12.90M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-121.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$13.00M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+839.8%
Year over year · more shares
Price change (1Y)
-58.7%
Trailing year
Short interest
0.8%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−19%
below
Price vs 50-day avg
−14%
below
RSI (14)
34
neutral
MACD trend
Negative
52-week position
3%
near low
Momentum
relative strength
1-month return
−11%
trailing
6-month return
−24%
trailing
YTD return
−15%
this year
Relative strength
−32%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 24 funds reported for Sep 30 · net 0 sh shares
Insider flow
Accumulating
Net +$59.1K over 90 days · 0% sells
Short interest
Falling
0.77% of float · ▼ -40.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
24 holders — near 3-yr high, broad support
Squeeze score
39
low risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+81%
Y/Y
Free cash flow
$-8.0M
Balance sheet
$21.0M
net cash
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−60%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−19%
Bearish
Price vs 50-day avg
−14%
Bearish
RSI (14)
34
Neutral
MACD trend
Negative
Bearish
52-week position
3%
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 24 funds reported for Sep 30 · net 0 sh shares
Insider flow
Accumulating
Net +$59.1K over 90 days · 0% sells
Short interest
Falling
0.77% of float · ▼ -40.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
24 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 3%
Range high $2
vs 200-day avg -19%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PHIO
this stock
Phio Pharmaceuticals Corp.
|
$10.36M | -15.0% | -100.0% | — | 0.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$131.39B | +13.5% | +46.2% | 30.2 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.6% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 13, 2026
- This year
- 21
Phio Pharmaceuticals completed its first commercial-scale cGMP batch of PH-762 drug substance on October 13, 2026, supporting planned Phase 2b clinical trial initiation in the first quarter of 2027.
ViewEarnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PHIO | -4.5% | -10.8% | -24.4% | -13.4% | -15.0% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -3.4% | -10.2% | -32.5% | -14.2% | -27.8% |